ID   HSJD-DIPG-007
AC   CVCL_VU70
SY   HSJD-DIPG007; DIPG007; Hospital Sant Joan de Deu-Diffuse Intrinsic Pontine Glioma-007
DR   cancercelllines; CVCL_VU70
DR   Cell_Model_Passport; SIDM01714
DR   DepMap; ACH-002348
DR   Wikidata; Q94303494
RX   PubMed=25628092;
RX   PubMed=27325687;
RX   PubMed=28947132;
RX   PubMed=31439867;
RX   PubMed=32229503;
RX   PubMed=34732238;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Unspecified (PubMed=27325687).
CC   Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=27325687; PubMed=34732238).
CC   Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Pro428Glnfs*3 (c.1283delC); Zygosity=Unspecified (PubMed=32229503; PubMed=34732238).
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Brainstem, pons; UBERON=UBERON_0000988.
ST   Source(s): PubMed=34732238
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 13
ST   D16S539: 13,14
ST   D21S11: 29,30
ST   D5S818: 13
ST   D7S820: 9,12
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C94764; Diffuse intrinsic pontine glioma
DI   ORDO; Orphanet_497188; Diffuse intrinsic pontine glioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   6Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 05-10-23; Version: 11
//
RX   PubMed=25628092; DOI=10.1038/bjc.2015.16;
RA   Cockle J.V., Picton S., Levesley J., Ilett E., Carcaboso A.M.,
RA   Short S., Steel L.P., Melcher A., Lawler S.E., Bruning-Richardson A.;
RT   "Cell migration in paediatric glioma; characterisation and potential
RT   therapeutic targeting.";
RL   Br. J. Cancer 112:693-703(2015).
//
RX   PubMed=27325687; DOI=10.1158/1535-7163.MCT-15-0558;
RA   Jansen M.H.A., Lagerweij T., Sewing A.C.P., Vugts D.J.,
RA   van Vuurden D.G., Molthoff C.F.M., Caretti V., Veringa S.J.E.,
RA   Petersen N., Carcaboso A.M., Noske D.P., Vandertop W.P., Wesseling P.,
RA   van Dongen G.A.M.S., Kaspers G.J.L., Hulleman E.;
RT   "Bevacizumab targeting diffuse intrinsic pontine glioma: results of
RT   89Zr-bevacizumab PET imaging in brain tumor models.";
RL   Mol. Cancer Ther. 15:2166-2174(2016).
//
RX   PubMed=28947132; DOI=10.1016/j.yexcr.2017.09.032;
RA   Meel M.H., Sewing A.C.P., Waranecki P., Metselaar D.S., Wedekind L.E.,
RA   Koster J., van Vuurden D.G., Kaspers G.J.L., Hulleman E.;
RT   "Culture methods of diffuse intrinsic pontine glioma cells determine
RT   response to targeted therapies.";
RL   Exp. Cell Res. 360:397-403(2017).
//
RX   PubMed=31439867; DOI=10.1038/s41467-019-11732-6;
RA   Fons N.R., Sundaram R.K., Breuer G.A., Peng S., McLean R.L.,
RA   Kalathil A.N., Schmidt M.S., Carvalho D.M., Mackay A., Jones C.,
RA   Carcaboso A.M., Nazarian J., Berens M.E., Brenner C., Bindra R.S.;
RT   "PPM1D mutations silence NAPRT gene expression and confer NAMPT
RT   inhibitor sensitivity in glioma.";
RL   Nat. Commun. 10:3790.1-3790.10(2019).
//
RX   PubMed=32229503; DOI=10.1158/1541-7786.MCR-19-0507;
RA   Wang Z.-H., Xu C., Diplas B.H., Moure C.J., Chen C.-P.J., Chen L.H.,
RA   Du C.-Z., Zhu H.-S., Greer P.K., Zhang L.-W., He Y.-P., Waitkus M.S.,
RA   Yan H.;
RT   "Targeting mutant PPM1D sensitizes diffuse intrinsic pontine glioma
RT   cells to the PARP inhibitor olaparib.";
RL   Mol. Cancer Res. 18:968-980(2020).
//
RX   PubMed=34732238; DOI=10.1186/s40478-021-01270-y;
RA   Xu C., Liu H., Pirozzi C.J., Chen L.H., Greer P.K., Diplas B.H.,
RA   Zhang L.-W., Waitkus M.S., He Y.-P., Yan H.;
RT   "TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are
RT   sensitive to a MDM2 antagonist.";
RL   Acta Neuropathol. Commun. 9:178.1-178.12(2021).
//